Phase 3 Readout~month

Phase 3 Topline: Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Mara

Indication
Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)

Other upcoming events for MIRM

Phase 2 ReadoutPhase 2 Readout: volixibat
Phase 2 ReadoutPhase 2 Readout: volixibat
Patent ExpiryPatent/Exclusivity Expiry: CTEXLI
Phase 3 ReadoutPhase 3 Topline: A Randomized, Open-label, Multicenter, Phase 3 Trial Evaluating Brelovitug vs Delayed Treatment for
Phase 3 ReadoutPhase 3 Topline: A Phase 2b/3, Open-Label, Multicenter Trial Evaluating the Efficacy and Safety of Switching to Brelo

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Mara — MIRM Phase 3 Readout | BioSniper